Pharmaceutical Research and Manufacturers of America (PhRMA)

Pharmaceutical Research and Manufacturers of America (PhRMA) website:

PhRMA "represents the leading research-based pharmaceutical and biotechnology companies in the United States". 

As of November 2004 its members include:

3M, Abbott Laboratories, Amgen, AstraZeneca, Aventis, Bayer, Berlex (part of Schering AG), Biogen Idec, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Pharmaceutical, Eli Lilly, Fujisawa Healthcare, GE Healthcare (part of General Electric), Genzyme, GlaxoSmithKline, Hoffmann-La Roche, Johnson & Johnson, Merck, Millennium Pharmaceuticals, Procter & Gamble, Novartis, Organon, Otsuka, Pfizer, Purdue Pharma, Sanofi-Aventis, Savient, Schering-Plough, Schwarz Pharma, Sepracor, Serono, Solvay, Valeant, Wyeth

Its affiliates and associates include:

aaiPharma, Accenture, Alkermes, Altana Pharma, Amylin, Automsoft, Boston Consulting Group, Celgene, Cephalon, CommonHealth, Compugen, Corus Pharma, Dendrite International, Eisai, Enzon, Ernst & Young, Euro RSCG Life, Eyetech Pharmaceuticals, FCB Healthcare, HealthSTAR Communications, ICOS, Idenix, IMS Health, Isis Pharmaceuticals, J. Scott International, KPMG, Maxim Pharmaceuticals, McGraw-Hill, McKesson, Medi-Promotions, Medicus Group, MediMedia, MGI Pharma, Nelson Communications, NOP World Health, Novo Nordisk, PDI, Penwest Pharmaceuticals, Quintiles Transnational, Saatchi, Sankyo Pharma, Sigma-Tau Pharmaceuticals, Stressgen Biotechnologies, Takeda Pharmaceuticals, TargetRx, Theravance, Thomson Healthcare, Vela Pharmaceuticals, Ventiv Health, Yamanouchi Pharma

PhRMA's current full list of members.

Get RSS feed of these results

Related stories and components

15 October 2014

USA: Video report on role of pharmaceutical & insurance companies in high price of cancer drugs

Author: CBS 60 Minutes (USA)

"The Cost of Cancer Drugs", 5 Oct 2014...

Read more

10 September 2013

Torching the Myths of Expensive Medicines

Author: Sebastian Krueger, Open Society Foundations

Patent protections allow for inflated monopoly pricing and keep generic drugs, which are cheaper, from going to market. Secret international trade deals impose the pharmaceutical companies’ high prices on foreign nations...But Fire in the Blood asks us...

Read more

21 September 2011

Battle of commercial interests confound fight against noncommunicable diseases

Author: David Brown, Washington Post

Behind...talks at the United Nations and a...document about the need to fight noncommunicable a fierce struggle between commercial and health interests...Some of the issues...are the same ones at the heart of...the battle against smoking...

Read more

23 February 2009

UN event brings together NGOs & pharmaceutical companies on initiatives to improve health in poor countries

See full story

23 February 2009

UN Reception Highlights Multi-Sector Partnerships in Global Public Health

Author: Global Health Progress Initiative

Promoting health among the world's poorest populations brought leaders from various nations, the global health community, biopharmaceutical companies, the media and international non-governmental organizations (NGOs) together today... The United...

Read more

23 February 2009

[video] Special Event on Philanthropy and the Global Public Health Agenda

Author: United Nations Economic and Social Council (ECOSOC)

Read more

23 June 2007

Thailand to buy more generic drugs from India

Author: Bloomberg

Thailand plans to buy more generic AIDS drugs from India to cut the cost of treating its poorest patients after failing to win large enough discounts from drug makers including Merck & Co. and Abbott Laboratories…Public health minister, Mongkol Na...

Read more

14 February 2007

Campaign to Stop Monopoly of Clinical Trial Data [India]

Author: Keya Acharya, Inter Press Service

Under the drug regulatory process any drug, whether patented or not, must pass safety, efficacy and quality tests for marketing from the Drug Controller-General of India (DGCI)...the DGCI can [currently] rely on previous test data to approve subsequent...

Read more

3 January 2007

Inside Abbott’s tactics to protect AIDS drug

Author: John Carreyrou, The Wall Street Journal [USA]

In the fall of 2003, Abbott Laboratories...seized on an unusual weapon that helped [its AIDS drug] Kaletra's global sales top $1 billion a year, even as it exposed Abbott to criticism that it was endangering patients. The weapon was an older Abbott...

Read more

31 May 2005

Despite Vow, Drug Makers Still Withhold Data [USA]

Author: Alex Berenson, New York Times

When the drug industry came under fire last summer for failing to disclose poor results from studies of antidepressants, major drug makers promised to provide more information about their research on new medicines...Eli Lilly and some other companies...

Read more